ONCOSEM ONKOLOJİK SİSTEMLER (ONCSM) — Income Statement
Detailed income statement with YoY comparison · latest 3A26
Income statement and cash flow are cumulative (6A = 6-month cumulative, 12A = full year). YoY Δ compares the same period last year.
| Line item | 3A26 | 12A25 | 9A25 | 6A25 | 3A25 | 12A24 | YoY Δ |
|---|---|---|---|---|---|---|---|
| Hasılat | 239.0M | 709.1M | 523.4M | 341.9M | 167.7M | 374.5M | +42.5% |
| Satışların Maliyeti | -108.7M | -389.2M | -328.8M | -227.2M | -95.0M | -236.0M | +14.4% |
| TİCARİ FAALİYETLERDEN BRÜT KAR (ZARAR) | 130.3M | 319.8M | 194.5M | 114.7M | 72.8M | 138.5M | +79.1% |
| BRÜT KAR (ZARAR) | 130.3M | 319.8M | 194.5M | 114.7M | 72.8M | 138.5M | +79.1% |
| Genel Yönetim Giderleri | -63.5M | -137.3M | -112.8M | -71.9M | -36.6M | -115.3M | +73.3% |
| Pazarlama Giderleri | -10.4M | -24.3M | -16.2M | -9.7M | -4.2M | -16.4M | +145.5% |
| Araştırma ve Geliştirme Giderleri | -504K | -1.2M | -808K | — | — | — | — |
| Esas Faaliyetlerden Diğer Gelirler | 921K | 3.6M | 2.9M | 1.6M | 995K | 2.5M | -7.4% |
| Esas Faaliyetlerden Diğer Giderler | -3.3M | -6.6M | -6.2M | -2.9M | -2.0M | -3.2M | +64.5% |
| ESAS FAALİYET KARI (ZARARI) | 53.6M | 154.0M | 61.5M | 31.8M | 30.9M | 6.2M | +73.4% |
| Yatırım Faaliyetlerinden Gelirler | 42K | 422K | 422K | 206K | 0 | 30K | — |
| FİNANSMAN GELİRİ (GİDERİ) ÖNCESİ FAALİYET KARI (ZARARI) | 53.6M | 154.5M | 62.0M | 32.0M | 30.9M | 6.2M | +73.5% |
| Finansman Gelirleri | 963K | 9.0M | 7.5M | 5.6M | 3.0M | 17.3M | -67.9% |
| Finansman Giderleri | -18.8M | -34.7M | -24.7M | -13.4M | -6.1M | -42.2M | +209.2% |
| Net Parasal Pozisyon Kazançları (Kayıpları) | -23.3M | -55.4M | -30.8M | -24.5M | -13.7M | -32.1M | +69.6% |
| SÜRDÜRÜLEN FAALİYETLER VERGİ ÖNCESİ KARI (ZARARI) | 12.5M | 73.4M | 13.9M | -404K | 14.1M | -50.8M | -11.2% |
| Sürdürülen Faaliyetler Vergi (Gideri) Geliri | -6.6M | -23.0M | 11.6M | 8.5M | -6.6M | -8.3M | +0.1% |
| Ertelenmiş Vergi (Gideri) Geliri | -6.6M | -13.3M | 11.6M | 8.5M | -6.6M | -8.3M | +0.1% |
| SÜRDÜRÜLEN FAALİYETLER DÖNEM KARI (ZARARI) | 5.9M | 50.4M | 25.5M | 8.1M | 7.5M | -59.2M | -21.1% |
| DÖNEM KARI (ZARARI) | 5.9M | 50.4M | 25.5M | 8.1M | 7.5M | -59.2M | -21.1% |
| Kontrol Gücü Olmayan Paylar | 0 | 0 | 0 | 0 | 0 | 0 | — |
| Ana Ortaklık Payları | 5.9M | 50.4M | 25.5M | 8.1M | 7.5M | -59.2M | -21.1% |
| Sürdürülen Faaliyetlerden Pay Başına Kazanç | 20.0M | — | — | — | — | — | — |
| Dönem Vergi (Gideri) Geliri | — | -9.7M | — | — | — | — | — |
| Yatırım Faaliyetlerinden Giderler | — | — | — | — | — | 0 | — |
ONCOSEM ONKOLOJİK SİSTEMLER (ONCSM) Income Statement
ONCOSEM ONKOLOJİK SİSTEMLER (ONCSM) Income Statement
This page shows the income statement of ONCOSEM ONKOLOJİK SİSTEMLER SANAYİ VE TİCARET A.Ş. (ONCSM) as reported to the Turkish Public Disclosure Platform (KAP), broken down line by line across the most recent periods, with year-over-year percentage change so you can compare each figure to the same period last year.
Latest period 3A26: TİCARİ FAALİYETLERDEN BRÜT KAR (ZARAR): 130.3M TL (YoY +79.1%) · BRÜT KAR (ZARAR): 130.3M TL (YoY +79.1%) · ESAS FAALİYET KARI (ZARARI): 53.6M TL (YoY +73.4%).
How to read this statement
The income statement and cash flow statement are cumulative: the 6-month column covers the first two quarters combined, the 9-month column the first three, and the full-year column all four. Compare each period to the same period last year (YoY) for a like-for-like view.
Frequently Asked Questions
Where does ONCSM's income statement data come from?
The figures are sourced from ONCOSEM ONKOLOJİK SİSTEMLER SANAYİ VE TİCARET A.Ş.'s official quarterly financial statements filed with KAP (the Turkish Public Disclosure Platform) and updated automatically after each new disclosure.
Is the income statement cumulative or per quarter?
The income statement and cash flow statement are cumulative within the year (6-month, 9-month, full-year), matching the official filings.
Is ONCSM financial data free on Borsafolio?
Yes. Balance sheet, income statement and cash flow statements for every BIST company are free and require no signup.